RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 6, 2010, Pages 1677-1681

  Saelee, Pensri ^a   Wongkham, Sopit ^b   Chariyalertsak, Sunanta ^a   Petmitr, Songsak ^c   Chuensumran, Ubol ^d  

^a NATIONAL CANCER INSTITUTE   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d SUAN DUSIT UNIVERSITY   (Thailand)

Author keywords

DNA methylation; Hepatocellular carcinoma; Methylation specific PCR; RASSF1A; Thailand

Indexed keywords

EID: 79956136713     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Agathanggelou A, Cooper WN, Latif F (2005). Role of the ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res, 65, 3497-508.
2. Agathanggelou A, Honorio S, Macartney DP, et al (2001). Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 20, 1509-18.
3. Burbee DG, Forgacs E, Zöchbauer-Müller S, et al (2001). Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst, 93, 691-9.
4. Byun DS, Lee MG, Chae KS, et al (2001). Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res, 61, 7034-8.
5. Dammann R, Li C, Yoon JH, et al (2000). Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet, 25, 315-9.
6. de La Coste A, Romagnolo B, Billuart P, et al (1998). Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A, 95, 8847-51.
7. De Souza AT, Hankins GR, Washington MK, et al (1995). M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet, 11, 447-9.
8. Donninger H, Vos MD, Clark GJ (2007). The RASSF1A tumor suppressor. J Cell Sci, 120, 3163-72.
9. Edmonson HA, Steiner PE (1954). Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer, 7, 462-503.
10. Elmileik H, Paterson AC, Kew MC (2005). Beta-catenin mutations and expression, 249serine p53 tumor suppressor gene mutation, and hepatitis B virus infection in southern African Blacks with hepatocellular carcinoma. J Surg Oncol, 91, 258-63.
11. Fischer JR, Ohnmacht U, Rieger N, et al (2007). Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer, 56, 115-23.
12. Kaneto H, Sasaki S, Yamamoto H, et al (2001). Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut, 48, 372-7.
13. Kim DH, Kim JS, Ji YI, et al (2003). Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res, 63, 3743-6.
14. Koul S, McKiernan JM, Narayan G, et al (2004). Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors. Mol Cancer, 3, 16.
15. Kuroki T, Trapasso F, Yendamuri S, et al (2003). Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. Clin Cancer Res, 9, 1441-5.
16. Lee MG, Kim HY, Byun DS, et al (2001). Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res, 61, 6688-92.
17. Lee S, Lee HJ, Kim JH, et al (2003). Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol, 163, 1371-8.
18. Lehmann U, Länger F, Feist H, et al (2002). Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol, 160, 605-12.
19. Lehmann U, Wingen LU, Brakensiek K, et al (2007). Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. Hum Mol Genet, 16, 1335-42.
20. Liu L, Yoon JH, Dammann R, et al (2002). Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene, 21, 6835-40.
21. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25, 402-8.
22. Lo KW, Kwong J, Hui AB, et al (2001). High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res, 61, 3877-81.
23. Macheiner D, Heller G, Kappel S, et al (2006). NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J Hepatol, 45, 81-9.
24. Miller SA, Dykes DD, Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16, 1215.
25. Motola-Kuba D, Zamora-Valdés D, Uribe M, et al (2006). Hepatocellular carcinoma. An overview. Ann Hepatol, 5, 16-24.
26. Müller HM, Widschwendter A, Fiegl H, et al (2003). DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res, 63, 7641-5.
27. Nakamura N, Carney JA, Jin L, et al (2005). RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest, 85, 1065-75.
28. Nishida N, Fukuda Y, Kokuryu H, et al (1993). Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res, 53, 368-72.
29. Nishida N, Fukuda Y, Komeda T, et al (1994). Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res, 54, 3107-10.
30. Okochi O, Hibi K, Sakai M, et al (2003). Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res, 9, 5295-8.
31. Parkin DM, Pisani P, Ferlay J (1999). Global cancer statistics. CA Cancer J Clin, 49, 33-64.
32. Schagdarsurengin U, Gimm O, Hoang-Vu C, et al (2002). Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res, 62, 3698-701.
33. Tomizawa Y, Kohno T, Kondo H, et al (2002). Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res, 8, 2362-8.
34. Wang J, Lee JJ, Wang L, et al (2004). Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res, 10, 6119-25.
35. Wang Y, Yu Z, Wang T, et al (2007). Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer, 56, 289-94.
36. Yakicier MC, Irmak MB, Romano A, et al (1999). Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene, 18, 4879-83.
37. Yang B, Guo M, Herman JG, et al (2003). Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol, 163, 1101-7.
38. Yeo W, Wong N, Wong WL, et al (2005). High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int, 25, 266-72.
39. Yoon JH, Dammann R, Pfeifer GP (2001). Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer, 94, 212-7.
40. Yoshida T, Ogata H, Kamio M, et al (2004). SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med, 199, 1701-7.
41. Zhang X, Xu HJ, Murakami Y, et al (1994). Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res, 54, 4177-82.
42. Zhang YJ, Ahsan H, Chen Y, et al (2002). High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol Carcinog, 35, 85-92.
43. Zhang YJ, Chen Y, Ahsan H, et al (2005). Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. Cancer Lett, 221, 135-43.
44. Zhang YJ, Wu HC, Shen J, et al (2007). Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res, 13, 378-84.
45. Zhong S, Tang MW, Yeo W, et al (2002). Silencing of GSTP1gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res, 8, 1087-92.
46. Zhong S, Yeo W, Tang MW, et al (2003). Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Clin Cancer Res, 9, 376-82.
47. Zhu GN, Zuo L, Zhou Q, et al (2004). Loss of heterozygosity on chromosome 10q22-10q23 and 22q11.2-22q12.1 and p53 gene in primary hepatocellular carcinoma. World J Gastroenterol, 10, 1975-8.